| Bioactivity | ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD)[1][2]. |
| Invitro | ABT-510 (1, 5, 10, 20, 50 nM; 24 h) induces apoptosis in ID8 cells and (50 nM; 24 h) increases the incidence of apoptosis in the human epithelial cancer cell lines SKOV3, OVCAR3, and CAOV3[1]. Apoptosis Analysis[1] Cell Line: |
| Name | ABT-510 |
| CAS | 251579-55-2 |
| Shortening | Ac-{Gly-Me}-GVIT-{Nva}-IRP |
| Formula | C46H83N13O11 |
| Molar Mass | 994.23 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
ABT-510
CAS: 251579-55-2 F: C46H83N13O11 W: 994.23
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.